Shortage of ADHD drugs continues as patients scramble to find medication

As of April 2025, the United States continues to experience a significant shortage of ADHD medications, including Adderall, Ritalin, and Vyvanse. This shortage began in late 2022 and has been attributed to increased demand, manufacturing delays, and regulatory constraints. The COVID-19 pandemic contributed to a surge in ADHD diagnoses and prescriptions, further straining the supply chain. Additionally, the classification of these medications as Schedule II controlled substances imposes strict production limits, complicating efforts to meet the heightened demand. Patients across the country are facing challenges in accessing their prescribed medications, leading to disruptions in treatment and increased stress. In response, the U.S. Drug Enforcement Administration has authorized increased production quotas for certain medicines like Vyvanse to alleviate the shortage. Healthcare providers work closely with patients to explore alternative treatments and manage care during this ongoing supply issue.

To Learn More:

US ADHD Stimulant Shortage Highlights Growing Challenges in Adult Treatment